SeaStar Medical Holding Corporation Common Stock (ICU)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for understandable, consistently profitable businesses with durable competitive advantages, conservative finances, and a margin of safety. SeaStar Medical is not that today. It is a commercial-stage healthcare company selling a selective cytopheretic device and QUELIMMUNE for hyperinflammation and acute kidney injury, with only 18 employees. Growth is visible but from a tiny base: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $615,000, up from $338,000 in fiscal Q2 2025, the quarter ended 2025-06-30. Net loss, however, widened to $3.7 million from $2.0 million. For FY2025, revenue was $1.2 million and net income was -$12.2 million; FY2024 revenue was $135,000 and net income was -$24.8 million. Trailing free cash flow was -$13.7 million, an FCF yield of -86.6% as a FairStock calculation. At the 2026-10-13 close of $3.59, the market cap is $15.8 million. FairStock calculations show P/E -1.90 and P/B 3.55, with ROE -356.87%. The Altman Z-Score is -24.39 and Piotroski F-Score is 4/9. Debt-to-equity of 0.03 is a modest positive. But there is no profitability, no clear moat, and no earnings-based valuation support. The computed Lynch category is none, because losses occurred in each of the last four years. Revenue growth of 68.94% and a 606.50% negative quarterly margin show scaling has not brought self-funding. This is speculative and not a Graham-style bargain.

In plain English: SeaStar Medical makes a device therapy meant to calm harmful inflammation in organs, and it sells a related therapy for children with sudden kidney injury. The business is very small: it has made no profit in the last four years and is burning cash, although sales are growing from a tiny base. At $3.59 a share as of the 2026-10-13 close, the price looks expensive next to today's sales and losses, so the numbers do not show a sturdy bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer